SCHEMBL22980250

SCHEMBL22980250

CC(C)(C)OC(=O)N1CC[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]1(C(=O)O)[Si](C)(C)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.32
RECQL P46063 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HPGD P15428 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
GPR119 Q8TDV5 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15512775 0.82 SMN1; SMN2 (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL143218 0.82 SMN1; SMN2 (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL4467232 0.80 PPM1D (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL4371165 0.77 RECQL (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL6026102 0.77 RECQL (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL4370444 0.77 RECQL (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL4371444 0.77 RECQL (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL2958649 0.77 RECQL (0.33) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL2956240 0.76 RECQL (0.32) HSD17B10RECQLUSP2SMN1; SMN2HPGD
SCHEMBL4370286 0.76 RECQL (0.32) HSD17B10RECQLUSP2SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010080-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2022-06-15 EP disclosed
WO-2021028643-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2021-02-18 WO disclosed